EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351	NDA	Gilead Sciences, Inc.	61958-2101-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-2101-1)	2016-03-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: April 26, 2026

Who supplies emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate for pharma manufacturing?

What does the supplier landscape look like for each API?

The three APIs are commonly sourced as either:

Direct API manufacturers (finished API lots with CoA)
Specialty chemical / API intermediates suppliers supporting API production (less visible in public filings)
CMO networks that source API from upstream plants and then formulate or package final drug products

Below are supplier profiles and the specific producer entities that show up in regulatory and market documentation for the APIs.

Emtricitabine (FTC): who supplies it?

What are the primary API producers named in the market?

Key emtricitabine API suppliers with established commercial manufacturing footprints include:

Gilead Sciences (emtricitabine is a core Gilead antiretroviral and is historically produced within its supply chain and partners)
Cipla (API manufacturing and antiretroviral supply chain presence)
Teva (API production footprint for antiretrovirals and HIV portfolio)
Mylan / Viatris (API supply via legacy Mylan capabilities)
Aurobindo Pharma (API production for antiretrovirals)
Torrent Pharmaceuticals (API manufacturing presence for HIV drugs in multiple markets)

Which specialty suppliers are active?

Synthon and Accord BioPharma are frequently listed in antiretroviral API supply chains and partnerships across multiple jurisdictions.

Rilpivirine hydrochloride (RPV-HCl): who supplies it?

What are the primary API producers named in the market?

Rilpivirine is a newer-generation NNRTI with a narrower set of fully scaled API suppliers. Named producers in antiretroviral sourcing include:

Jubilant Pharma (API manufacturing footprint and antiretroviral supply presence)
Cipla (API manufacturing and HIV portfolio presence)
Teva (API production footprint)
Aurobindo Pharma (API manufacturing presence for antiretrovirals)
MacLeods (API manufacturing footprint in specialty and antiretroviral production networks)

What supply channels dominate?

Rilpivirine API sourcing usually runs through a combination of:

Direct API manufacturers supplying generic and branded producers
CMO-managed procurement, where the final drug manufacturer contracts downstream but specifies qualified upstream API vendors

Tenofovir alafenamide fumarate (TAF): who supplies it?

What are the primary API producers named in the market?

Tenofovir alafenamide fumarate has a concentrated supplier base due to process complexity and quality requirements.

Named API manufacturers with visible industry presence include:

Gilead Sciences (TAF is Gilead’s core chemistry; Gilead supply and partnered manufacturing appear across global sourcing)
Mylan / Viatris (TAF and TAF-related antiretroviral supply presence through portfolio expansion)
Teva (antiretroviral API footprint)
Aurobindo Pharma (TAF supply presence in generic antiretroviral pipelines)
Cipla (antiretroviral API manufacturing presence)

Which companies appear in upstream process ecosystems?

TAF and its salts typically rely on upstream intermediate suppliers for:

Tenofovir prodrug intermediates
Stereochemical and phosphorylation step support
Controlled crystallization and salt formation (fumarate)

In practice, these intermediates are often produced by specialty chemical plants that supply multiple API players.

Supplier decision matrix for procurement (API-level)

How do buyers typically choose among suppliers?

For each API, procurement tends to weight:

Regulatory history: whether the supplier has DMF/CEP history in key markets (US and EU)
Batch consistency: impurity profile stability and control strategy maturity
Salt form and specifications: especially critical for rilpivirine hydrochloride and TAF fumarate
Manufacturing footprint: cGMP compliance and tech-transfer track record

Market reality: supplier concentration by API

How concentrated is supply across these three APIs?

Emtricitabine (FTC) is relatively more supply-diverse due to long commercial life and multiple generic approvals.
Rilpivirine hydrochloride (RPV-HCl) is more concentrated due to narrower demand and higher synthesis qualification barriers.
Tenofovir alafenamide fumarate (TAF) is typically the most concentrated because the prodrug synthesis, purification, and salt/crystallization requirements are harder to scale quickly.

Recommended sourcing structure for drug manufacturers

What procurement structure reduces supply risk?

A stable and audit-ready procurement model usually uses:

At least two qualified API suppliers per API where market conditions allow
A secondary CMO-qualified upstream path (supplier-of-supplier) to address single-site outages
Written specification lock tied to regulatory filings (impurities, polymorph/crystal form, residual solvents)

Key Takeaways

Emtricitabine (FTC) has the broadest set of commercially active API suppliers in the three.
Rilpivirine hydrochloride (RPV-HCl) has a smaller supplier base, increasing reliance on fewer qualified plants.
Tenofovir alafenamide fumarate (TAF) typically shows the highest supplier concentration due to manufacturing and quality complexity.
The practical buyer approach is dual sourcing per API plus CMO-managed qualification to protect continuity.

FAQs

Who is the most reliable source for each API?

Reliability is highest among suppliers with established regulatory dossiers and continuous commercial batch history, including large antiretroviral manufacturers with a long footprint in HIV APIs.

Are these APIs usually sourced from the innovator or from generics supply chains?

Both. Innovator-aligned supply appears for core molecules, while generics and branded generics often procure from qualified API producers with DMF or equivalent documentation.

Is salt form a critical quality constraint for rilpivirine and TAF?

Yes. Rilpivirine hydrochloride and TAF fumarate require tight control of identity, impurity profile, and physical form attributes tied to specifications.

How do buyers qualify new API suppliers for HIV drugs?

Through regulatory dossier history, cGMP compliance checks, impurity/trace controls verification, and process and analytical method transfer.

What drives supplier switching risk for these APIs?

Process complexity, impurity sensitivity, and the time needed to rebuild acceptance across finished-dose stability and bioequivalence packages.

References (APA)

[1] U.S. FDA, Center for Drug Evaluation and Research. (n.d.). Drug master files (DMF) and regulatory guidance resources. https://www.fda.gov/drugs
[2] European Medicines Agency. (n.d.). European patent and medicines regulatory information resources (CEP and validation pathways). https://www.ema.europa.eu
[3] Gilead Sciences. (n.d.). HIV medicines portfolio and manufacturing/supply information (corporate resources). https://www.gilead.com
[4] Viatris. (n.d.). Pharmaceutical manufacturing and API portfolio resources (corporate information). https://www.viatris.com

Suppliers and packagers for generic pharmaceutical drug: EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE